Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
MicroRNAs01:22

MicroRNAs

21.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Metastasis02:30

Metastasis

5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

11.5K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.5K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

7.3K
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.3K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Long Noncoding Rna Malat-1: A Versatile Regulator In Cancer Progression, Metastasis, Immunity, And Therapeutic Resistance.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Long Noncoding Rna Malat-1: A Versatile Regulator In Cancer Progression, Metastasis, Immunity, And Therapeutic Resistance.

Related Experiment Video

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K

Long noncoding RNA MALAT-1: A versatile regulator in cancer progression, metastasis, immunity, and therapeutic resistance.

Dexin Xu1, Wenhai Wang2, Duo Wang3

  • 1Department of Orthopedics, Jilin Province FAW General Hospital, Changchun, 130000, China.

Non-Coding RNA Research
|March 21, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Long noncoding RNA MALAT-1 is a key regulator in cancer, impacting metastasis, drug resistance, and immune evasion. Targeting MALAT-1 offers a promising strategy for improving cancer therapies and overcoming treatment resistance.

Keywords:
Cancer immunityChemoresistanceImmunotherapyTumor microenvironment

More Related Videos

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA
09:36

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA

Published on: April 10, 2018

25.3K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

300

Related Experiment Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K
RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA
09:36

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA

Published on: April 10, 2018

25.3K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

300

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Immunology

Background:

  • Long noncoding RNAs (lncRNAs) are non-protein-coding transcripts implicated in cancer.
  • Metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1) is a lncRNA linked to cancer progression.
  • MALAT-1 influences key cancer hallmarks like proliferation, invasion, and metastasis.

Purpose of the Study:

  • To highlight the multifaceted role of MALAT-1 in cancer development and progression.
  • To explore MALAT-1's involvement in drug resistance and its potential as a therapeutic target.
  • To elucidate MALAT-1's impact on anti-tumor immunity and immune evasion.

Main Methods:

  • Review of existing literature on MALAT-1 function in cancer.
  • Analysis of MALAT-1's molecular mechanisms in regulating cancer hallmarks.
lncRNA MALAT-1
  • Examination of MALAT-1's influence on immunomodulatory molecules and immune cell populations.

    • Main Results:

    • MALAT-1 significantly contributes to cancer hallmarks, including proliferation, invasion, and epithelial-mesenchymal transition (EMT).
    • MALAT-1 is implicated in chemoresistance, presenting it as a target to overcome treatment refractoriness.
    • MALAT-1 modulates immune responses by affecting MHC proteins and PD-L1, promoting immune evasion and regulating immune cell populations.

    Conclusions:

    • MALAT-1 is a versatile regulator in cancer, affecting tumorigenesis, chemoresistance, and immunotherapy.
    • Targeting MALAT-1 holds promise for developing novel cancer therapies and improving treatment outcomes.
    • Further research is essential to fully understand MALAT-1's role and translate findings into clinical applications.